A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
National Cancer Institute (NCI)
TCR2 Therapeutics
TCR2 Therapeutics
NGM Biopharmaceuticals, Inc